曲妥珠单抗在晚乳腺癌研究.ppt

Reference Data on file. Genentech USA, Inc., CA, USA and F Hoffmann-La Roche Ltd., Basel, Switzerland. Reference Data on file. Genentech USA, Inc., CA, USA and F Hoffmann-La Roche Ltd., Basel, Switzerland. Reference Data on file. Genentech USA, Inc., CA, USA and F Hoffmann-La Roche Ltd., Basel, Switzerland. Reference Data on file. Genentech USA, Inc., CA, USA and F Hoffmann-La Roche Ltd., Basel, Switzerland. Reference Data on file. Genentech USA, Inc., CA, USA and F Hoffmann-La Roche Ltd., Basel, Switzerland. * * * 本材料/幻灯片包含了部分适应症以外的信息，仅供内部沟通，不能用于临床推广。 * * 本材料/幻灯片包含了部分适应症以外的信息，仅供内部沟通，不能用于临床推广。 * * * * * 小结与启示：曲妥珠单抗?治疗进展后持续使用长期获益 一线治疗7年 OS率为 17% (n= 220) 当曲妥珠单抗? 持续治疗到疾病进展，OS率显著提高 (12.3% vs. 5.4%; P0.0001) 当曲妥珠单抗? 持续治疗到疾病进展，中位OS显著提高 (3.1 vs. 1.45 year 法国观察研究长期随访资料为曲妥珠单抗?治疗进展后使用取得长期获益增添了证据 617 General Poster Session (Board #11C), Mon, 1:00 PM-5:00 PM Long-term survival in patients with HER2-positive metastatic breast cancer treated with trastuzumab as first-line therapy: Seven-year follow-up of the French Observational Hermine Study. E. Antoine, F. Dalenc, C. Hebert, P. Rivera, G. Romieu, N. Varoqueaux, J. P. Guastalla, M. Namer; Clinique Hartmann, Neuilly-sur-Seine, France; Institut Claudius Regaud, Toulouse, France; Centre Antoine-Lacassagne, Nice, France; CHU Toulouse Rangueil, Toulouse, France; CRLC Val d’Aurelle, Montpellier, France; Roche, Neuilly-sur-Seine, France; Centre Léon Bérard, Lyon, France Background: The Hermine study observed the use of trastuzumab (TZ) in HER2-positive metastatic breast cancer (MBC) in routine practice (in first (1st)-, second-, or third-line and beyond in 220, 138, and 243 patients, respectively), including patients who received TZ beyond progression (TBP). The 2-year OS estimate was 58% for 1st line patients. Because of the short follow-up (FUP) duration, few data exist on long-term survival of patients treated with TZ in this setting. Methods: The primary objective of our study was to describe and update the overall sur